DUBLIN--(BUSINESS WIRE)--The "Glaucoma Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global glaucoma therapeutics market size reached US$ 7 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 10.2 Billion by 2027, exhibiting a CAGR of 6.48% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The increasing prevalence of glaucoma across the globe represents one of the key factors driving the growth of the market. Glaucoma is highly prevalent in patients with diabetes and other eye disorders, such as age-related macular degeneration (AMD), cataract and dry eye.
In line with this, the rising geriatric population, which is more susceptible to such ailments, is creating a positive outlook for the market growth. Furthermore, increasing health consciousness among the masses and rising preference for laser glaucoma surgery is also driving the market growth.
Additionally, the development of innovative combination drugs is acting as another growth-inducing factor. Pharmaceutical manufacturers are creating anti-glaucoma drugs and prostaglandin analogs combined with two or more drugs to control the elevated levels of IOP. Other factors, including the advent of advanced glaucoma diagnostic techniques, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, indication and end user.
Breakup by Drug Class:
- Prostaglandin Analogs
- Beta Blockers
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Others
Breakup by Indication:
- Open Angle Glaucoma
- Angle Closure Glaucoma
- Others
Breakup by End User:
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgery Centers
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
5 Global Glaucoma Therapeutics Market
6 Market Breakup by Drug Class
7 Market Breakup by Indication
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Price Analysis
14 Competitive Landscape
Companies Mentioned
- Aerie Pharmaceuticals Inc.
- Allergan Plc
- Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
- Inotek Pharmaceuticals Corp.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Santen Pharmaceutical Co. Ltd.
- SIFI S.p.A
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/h57pzq
